COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS
First Claim
Patent Images
1. A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a human PD-1 axis binding antagonist and an OX40 binding agonist, wherein the individual has cancer or has been diagnosed with cancer, and wherein the cancer cells in a tumor sample of the cancer from the individual do not express PD-L1.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.
45 Citations
124 Claims
-
1. A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a human PD-1 axis binding antagonist and an OX40 binding agonist, wherein the individual has cancer or has been diagnosed with cancer, and wherein the cancer cells in a tumor sample of the cancer from the individual do not express PD-L1.
-
2. (canceled)
-
3. (canceled)
- 4. A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a human PD-1 axis binding antagonist and an OX40 binding agonist, wherein the individual has cancer or has been diagnosed with cancer, and wherein the cancer cells in a tumor sample of the cancer from the individual express PD-L1.
-
5. (canceled)
-
8-10. -10. (canceled)
-
15-19. -19. (canceled)
-
22-28. -28. (canceled)
-
31. (canceled)
-
32. (canceled)
-
37-39. -39. (canceled)
-
41. (canceled)
-
45. (canceled)
-
49. (canceled)
-
50. A method of enhancing immune function in an individual having cancer comprising administering an effective amount of a PD-1 axis binding antagonist and an OX40 binding agonist, wherein the individual has been diagnosed with cancer, and wherein the cancer cells in a tumor sample of the cancer from the individual do not express PD-L1.
-
51. (canceled)
-
52. (canceled)
-
53. A method of enhancing immune function in an individual having cancer comprising administering an effective amount of a PD-1 axis binding antagonist and an OX40 binding agonist, wherein the individual has been diagnosed with cancer, and wherein the cancer cells in a tumor sample of the cancer from the individual express PD-L1.
-
54-109. -109. (canceled)
-
111-119. -119. (canceled)
-
120. A kit comprising a medicament comprising a PD-1 axis binding antagonist and an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the medicament in combination with a composition comprising an OX40 binding agonist and an optional pharmaceutically acceptable carrier for treating or delaying progression of cancer in an individual, wherein cells in a tumor sample of the cancer from the individual express PD-L1.
-
121. (canceled)
-
122. A kit comprising a first medicament comprising a PD-1 axis binding antagonist and an optional pharmaceutically acceptable carrier, and a second medicament comprising an OX40 binding agonist and an optional pharmaceutically acceptable carrier, wherein the kit further comprises a package insert comprising instructions for administration of the first medicament and the second medicament for treating or delaying progression of cancer in an individual, wherein cells in a tumor sample of the cancer from the individual express PD-L1.
-
123. (canceled)
-
124. A kit comprising a medicament comprising an OX40 binding agonist and an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the medicament in combination with a composition comprising a PD-1 axis binding antagonist and an optional pharmaceutically acceptable carrier for treating or delaying progression of cancer in an individual, wherein cells in a tumor sample of the cancer from the individual express PD-L1.
Specification